As reported, an increasing number of clinical trials have demonstrated that locoregional therapy, including TACE or HAIC, combined with TKIs and/or PD-1 inhibitors possessed favorable outcomes in advanced HCC patients, comparing to monotherapy or dual combination therapy (Kulik and El-Serag, 2019). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.